## Contents

amfAR in 2012: Program Highlights 04

Grants, Fellowships, and Awards 07

- Research Grants
- TREAT Asia Awards
- GMT Initiative Awards
- Public Policy Awards

Message from the Treasurer and the Chair of the Finance and Budget Committee 13

Financial Highlights 14

Leadership and Advisory Committees 16

- Board of Trustees
- Scientific Advisory Committee
- Program Advisory Council
- Management Group

---

amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research.
From the Chairman and the CEO

Dear Friends and Supporters,

An amfAR grant awarded at the tail end of fiscal year 2012 contributed to one of the biggest HIV research breakthroughs of recent years. The grant, made under the auspices of our amfAR Research Consortium on HIV Eradication (ARCHE), enabled a team of scientists to establish a research collaboratory to explore and document possible pediatric HIV cure cases. It was through their coordinated efforts that the historic first case of a child being cured of HIV was verified and subsequently reported in March 2013.

The case appears to hinge on the fact that this “Mississippi child” was treated with a cocktail of antiretroviral drugs soon after birth. While the child continues to be monitored and the case has yet to be replicated, it adds to a growing body of knowledge about a potential HIV cure, much of it being generated by scientists working collaboratively under amfAR’s three-year old ARCHE program.

This exciting development capped a productive year in which we awarded 34 new research grants and fellowships, and amfAR-funded investigators published more than 40 research papers in leading scientific journals.

Research continues to drive our international programs, too, as we strive to resolve unanswered questions, fill gaps in data, and determine which interventions are most effective for particular populations. Through our policy program, we continue to work with elected officials to ensure that AIDS-related public policies are informed by the science and that critical programs are adequately resourced.

As always, none of this important work would be possible without your generous support, and we thank you for playing your part in our collective progress toward an AIDS-free future.

Kenneth Cole
Chairman of the Board

Kevin Robert Frost
Chief Executive Officer
amfAR in 2012: Program Highlights

Research

• In June 2012, a think tank organized by amfAR in San Francisco brought together 12 scientists involved in various aspects of HIV cure research, along with two bioethicists, to explore the potential for an HIV cure in infants and children. As a result, amfAR awarded a grant to Drs. Deborah Persaud of Johns Hopkins Children’s Center and Katherine Luzuriaga of the University of Massachusetts to establish a pediatric research collaboratory to investigate possible cases of an HIV cure in children. Shortly thereafter, the researchers were able to document the historic first case of a child being cured of HIV (reported in March 2013).

• amfAR awarded more than $5 million in grants and fellowships to support 34 research projects in 2012. Many of these awards were for cure-focused studies aimed at answering critical questions such as how, where, and why does HIV persist in infected people—even while they are on antiretroviral therapy (ART). Five of the recipients were junior investigators who received Mathilde Krim Fellowships in Basic Biomedical Research.

• amfAR continues to advance cure research through its amfAR Research Consortium on HIV Eradication (ARCHE). In 2012, more than $1.5 million in funding went to seven collaborative teams of researchers working in areas considered central to HIV eradication: pinpointing the location of all the viral reservoirs where HIV hides in the body; determining how these reservoirs are formed and why they persist despite antiretroviral therapy; finding more accurate ways of measuring the size of the reservoirs; and finding a way to eliminate the reservoirs altogether.

• ARCHE grantees continue to build on previous progress made with amfAR funding. Dr. Sarah Palmer is researching virus clones, seeking to understand how they arise and what they mean for efforts to rid the body of HIV. Dr. Robert Siliciano’s prior ARCHE research identified a drug that reactivates dormant virus so that it can be treated with antiretroviral therapy. Continuing with this line of study, Dr. Siliciano is determined to understand the mechanism behind HIV’s ability to remain latent and the important ramifications it has for the design of future cure strategies. And Dr. David Margolis aims to develop an ultra-sensitive method of detecting virus, which could be used in a laboratory as well as clinical setting.

• amfAR played a prominent role in research-focused programming at the 2012 International AIDS Conference. Vice President and Director of Research Dr. Rowena Johnston participated in a two-day pre-conference cure symposium—titled “Towards and HIV Cure”—co-chaired by Nobel prize-winning scientist Dr. Françoise Barré-Sinoussi and Dr. Steven Deeks. Dr. Johnston also co-chaired a conference session titled “Gender and Science: Shifting the Paradigm in HIV Research.”

• Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In 2012, more than 40 scientific publications resulted from amfAR-funded research.

TREAT Asia

• TREAT Asia (Therapeutics Research, Education, and AIDS Training in Asia) is a network of clinics, hospitals, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments throughout Asia and the Pacific. Facilitated by amfAR, TREAT Asia seeks to strengthen HIV/AIDS care, treatment, and management skills among health care professionals through education and training programs developed by experts in the region.

• In December 2011, ViiV Healthcare continued its productive partnership with TREAT Asia by awarding a new grant to address the healthcare challenges HIV-positive children face as they age into adolescence. Research supported by this funding is focusing on integrating reproductive healthcare, treatment adherence among teenagers, and studying the risk of bone damage due to lifelong ART.

• With support from Merck, TREAT Asia organized educational activities in advance of a “test and treat” pilot study with men who have sex with men (MSM) and transgender women (TG) conducted by the Thai Red Cross AIDS Research Centre in three provinces in Thailand. As part of a community preparedness and consultation component leading up to the project, TREAT Asia held a forum in Bangkok in May 2012.

• Nurses and counselors from Lampang Hospital, Thailand, attended a “test and treat” workshop organized by TREAT Asia in June, 2012.
to gauge MSM/TG community leaders’ interest in “test and treat” and discuss the potential benefits and limitations of the strategy.

- In 2012, TREAT Asia was awarded a new grant from the U.S. National Institutes of Health (NIH) to study human papillomavirus, the cause of cervical and anal cancer, in perinatally HIV-infected female and male adolescents in Thailand and Vietnam. The grant builds on earlier research conducted with the Thai Red Cross AIDS Research Centre. This innovative study reflects TREAT Asia’s growing commitment to better understanding the long-term impact of HIV on adolescents growing up with the infection.

- In 2011, the NIH renewed a major research grant to support TREAT Asia’s work in the Asia-Pacific region for a second five-year period. As the regional representative of the International Epidemiology Databases to Evaluate AIDS (IeDEA) since 2006, TREAT Asia has been contributing data from its adult and pediatric observational cohorts to a global database that allows researchers to address key questions about ART outcomes and how best to optimize treatment approaches.

Public Policy

- Through its public policy office in Washington, D.C., amfAR educates policy makers, the media, and the public about evidence-based policies to address HIV/AIDS in the U.S. and around the world. In 2012, amfAR continued to promote rational AIDS-related policies based on the most current scientific knowledge.

- In June 2012, amfAR held a Capitol Hill briefing in Washington, D.C., bringing together researchers at the cutting edge of scientific discovery to discuss a range of novel approaches being explored in the search for a cure for HIV/AIDS. The highly informative panel discussion covered topics such as stem cells, gene therapy, medications, and immune response modifications such as therapeutic vaccines. The event also featured an engrossing conversation between renowned broadcast journalist Judy Woodruff and Timothy Brown, the “Berlin Patient,” the first and only person known to be cured of HIV.

- Other Capitol Hill briefings in 2012 focused on combination prevention approaches and the research agenda needed to end the HIV epidemic, with participants including U.S. Global AIDS Coordinator Dr. Eric Goosby and Dr. Chris Beyrer of the Johns Hopkins Center for Public Health and Human Rights.

- At the International AIDS Conference, amfAR released an “Action Agenda to End AIDS,” developed with AVAC to identify five major short-term priorities for global AIDS programs together with realistic, annual targets that must be achieved through 2015. The report was the focus of a satellite session at the conference titled “Getting Real About Getting to the End of AIDS.” A panel discussion moderated by renowned journalist Charlayne Hunter-Gault included Anthony Fauci, M.D., director of the National Institute for Allergy and Infectious Diseases; Mike Cohen, M.D., professor of epidemiology at the University of North Carolina; Helen Rees, M.D., executive director of the Wits Reproductive Health and HIV Institute in South Africa; Mitchell Warren, executive director of AVAC; Chris Collins, amfAR vice president and director of public policy; and other leading AIDS experts.

- amfAR also produced a range of informative reports and issue briefs in FY2012, covering topics such as The Effect of Budget Sequestration on Global Health, Ending the HIV Epidemic Among Gay Men in the United States, and Estimating the Human Impact of Global Health Funding in the President’s Fiscal Year 2013 Budget Proposal.

GMT Initiative (formerly MSM Initiative)

- Since 2007, amfAR has been serving the HIV-related needs of gay men, other men who have sex with men (MSM), and transgender individuals (collectively, GMT) throughout the developing world through its MSM Initiative. The program was recently renamed The GMT Initiative to better reflect the diversity of the people it serves. Through small, targeted grants to grassroots groups, amfAR helps expand access to HIV education and prevention services; supports advocacy aimed at increasing funding for prevention and treatment services; and works to end the stigma, discrimination, and violence that threaten the lives of GMT and fuel the spread of HIV/AIDS.
In 2012, amfAR made community awards totaling more than $650,000 to 39 organizations throughout its five target regions: Africa, Asia-Pacific, the Caribbean, Eastern Europe and Central Asia, and Latin America. The awards support the work of grassroots groups working to reduce the spread and impact of HIV among GMT in hard hit regions of the developing world.

The GMT Initiative also made five awards as part of its Advocacy in Action program, which supports GMT-led community-based organizations that wish to influence policies of governments and external donors, and six awards for its Evidence in Action program, which funds and evaluates community-led programs for scale-up, utilizing the science of combination strategies. The awards for these two programs in 2012 totaled more than $180,000.

With the Johns Hopkins Bloomberg School of Public Health, amfAR published Achieving an AIDS-Free Generation for Gay Men and Other MSM, a new report providing the most comprehensive analysis to date of HIV-related funding and programming for this population.

In November 2011, amfAR published a Fundraising Toolkit for GMT-led advocacy in low- and middle-income countries, offering general tips on fundraising and information about who is funding GMT groups. The toolkit is available in English, Russian, and Spanish.

Public Information

amfAR continued to work closely with the media in 2012 to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS press coverage. Articles and reports involving amfAR were carried in numerous media outlets, including The New York Times, The Wall Street Journal, The Washington Post, the Associated Press, Reuters, Bloomberg News, and The Huffington Post.


amfAR has long benefited from the voices and the visibility of a wide range of prominent public figures. In 2012, these supporters included amfAR’s Global Fundraising Chairman Sharon Stone, amfAR ambassadors Cheyenne Jackson, Janet Jackson, Milla Jovovich, Liza Minnelli, and Michelle Yeoh, as well as Sarah Jessica Parker, Heidi Klum, Alan Cumming, John Benjamin Hickey, Janelle Monae, Jennifer Hudson, Elizabeth Hurley, Debbie Harry, Diane Kruger, Kylie Minogue, fun., Jessie J, Theophilus London, Chris Tucker, Adrien Brody, Dita Von Teese, Stanley Tucci, Chelsea Handler, and Katy Perry, among many others.

amfAR publishes a wide range of educational materials, program reports, and periodicals in an effort to communicate the Foundation’s message and the need for AIDS research. Periodicals produced in both print and electronic formats in 2012 included: Innovations, amfAR’s newsletter; the TREAT Asia Report, distributed widely to an international audience; and a monthly email newsletter distributed to more than 54,000 subscribers.
2012 RESEARCH FELLOWSHIPS, GRANTS, AND AWARDS

All projects listed below were awarded amfAR funding during the period October 1, 2011, through September 30, 2012.

amfAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE)

HIV persistence after successful CCR5-depleted stem cell transplantation
Principal Investigator: Steven Deeks, M.D.
University of California, San Francisco
San Francisco, CA
$47,410

Short-term disulfiram administration to reverse latent HIV infection
Principal Investigator: Julian Elliott, Ph.D.
Monash University
Clayton, Australia
$119,926

HIV-1 reservoir reduction following allogeneic stem cell transplantation
Principal Investigator: Timothy Henrich, M.D.
The Brigham and Women’s Hospital, Inc.
Boston, MA
$105,160

Detection and measurement of the HIV reservoir
Principal Investigator: Una O’Doherty, M.D., Ph.D.
University of Pennsylvania
Philadelphia, PA
$96,000

Identifying the T-cell clonotypes producing persistent virus
Principal Investigator: Sarah Palmer, Ph.D.
Swedish Institute for Infectious Disease Control and Karolinska Institutet
Solna, Sweden
$164,743

Quantifying HIV persistence under early HAART in children
Principal Investigator: Deborah Persaud, M.D.
Johns Hopkins University
Baltimore, MD
$239,599

Identification of drugs that promote the death of latently infected cells
Principal Investigator: Robert Siliciano, M.D., Ph.D.
Johns Hopkins University
Baltimore, MD
$120,000

Reactivation of latent HIV-1 through a novel pathway
Principal Investigator: Robert Siliciano, M.D., Ph.D.
Johns Hopkins University
Baltimore, MD
$120,000

Analysis of non-induced provirus as a barrier to HIV eradication
Principal Investigator: Robert Siliciano, M.D., Ph.D.
Johns Hopkins University
Baltimore, MD
$120,000

MATHILDE KRIM FELLOWS IN BASIC BIOMEDICAL RESEARCH

Preventing HIV Transmission

Regulation of epitope-specific antibodies against HIV-1 Env
Mattias Forsell, Ph.D.
Karolinska Institutet
Stockholm, Sweden
$125,000

Discovery of antisense-encoded proteins as novel AIDS vaccine targets
Nicholas Maness, Ph.D.
Tulane University
New Orleans, LA
$80,000 (Phase II)

Optimizing Treatment

SAMHD1-mediated restriction of HIV-1 infection of myeloid cells
Katarzyna Hrecka, Ph.D.
Case Western Reserve University
Cleveland, OH
$124,962

Identification of novel RNA-protein interactions in HIV-1 particle genesis
Sebila Bulent Kutluay, Ph.D.
Aaron Diamond AIDS Research Center
New York, NY
$125,000

Lentiviral resistance to Tetherin/BST-2 antagonists and HDACs
Ruth Serra-Moreno, Ph.D.
New England Primate Research Center
Southborough, MA
$125,000

RESEARCH GRANTS

Pursuing HIV Eradication

Impact of TLR ligands mediated IL-10 production on HIV persistence
Franck Dupuy, Ph.D.
Vaccine and Gene Therapy Institute of Florida
Port St. Lucie, FL
$125,000

An atlas of HIV-1 reservoirs, compartments and drug resistant sanctuaries
Richard Fox, Ph.D.
University of Washington
Seattle, WA
$125,000

Ex vivo modeling of viral reactivation in virally suppressed subjects
Rémi Fromentin, PharmD., Ph.D.
Vaccine and Gene Therapy Institute of Florida
Port St. Lucie, FL
$125,000

Purging HIV proviral transcription by targeting activation of P-TEFb
Uri Mboonye, Ph.D.
Case Western Reserve University
Cleveland, OH
$125,000

Brain HIV reservoirs: their role in cognitive impairment in the ART era
Katherine Thompson, Ph.D.
Monash University
Clayton, Australia
$124,995

RESEARCH FELLOWSHIPS

Pursuing HIV Eradication

Ongoing replication in anatomical niches in the face of ART
David Baltimore, Ph.D.
California Institute of Technology
Pasadena, CA
$249,600

The role of dendritic cells in HIV-1 latency
Paul Cameron, Ph.D.
Monash University
Melbourne, Australia
$120,000

Reactivation of HIV transcription via PKC agonists and HDACs
Koh Fujinaga, Ph.D.
University of California, San Francisco
San Francisco, CA
$120,000

Administration of an ACE-inhibitor to decrease the latent reservoir
Hiroyu Hatano, M.D.
University of California, San Francisco
San Francisco, CA
$120,000

Identification of cellular factors required to maintain HIV latency
Jonathan Karn, Ph.D.
Case Western Reserve University
Cleveland, OH
$250,000
T memory stem cells: a new cellular reservoir for HIV-1
Mathias Lichterfeld, M.D.
Massachusetts General Hospital
Boston, MA
$250,000

Eliminating the latent reservoir through self-specific antibodies
Douglas Nixon, M.D.
University of California, San Francisco
San Francisco, CA
$120,000

Biomarkers of virologic control in early-treated HIV-seronegative children
Deborah Persaud, M.D.
Johns Hopkins University
Baltimore, MD
$120,000

Characterization and inhibition of the macrophage reservoir of HIV-1
Quentin Sattentau, Ph.D.
University of Oxford
Oxford, United Kingdom
$120,000

CD4+ T cell subsets: targets for HIV infection and latency
John Tilton, M.D.
Case Western Reserve University
Cleveland, OH
$120,000

Size of the HIV reservoir and ongoing replication in defined patient cohorts
Linos Vandekerckhove, M.D., Ph.D.
Ghent University Hospital
Ghent, Belgium
$249,600

Sulfonation-dependent reactivation in primary T cell models of HIV latency
John Tilson, M.D.
Case Western Reserve University
Cleveland, OH
$120,000

RESEARCH AWARDS
Optimizing Treatment
Assessing the impact of HIV/AIDS service delivery in Malawi: Zomba District ART observational cohort study
Sumeet Sodhi, M.D., M.P.H.
Dignitas International
Toronto, Canada
$125,000

2012 TREAT ASIA GRANTS AND AWARDS

Treat Asia HIV Observational Database (TAHOD)

Romanee Chaikwairith, M.D., M.H.S.
Chiang Mai University
Chiang Mai, Thailand
$20,000*

Yi-Ming Chen, M.D., Sc.D.
National Yang-Ming University
Taipei, Taiwan
$20,000*

Jun Yong Choi, M.D., Ph.D.
Yonsei University College of Medicine
Seoul, South Korea
$16,500*

Rossana Ditangco, M.D.
Asian Foundation for Tropical Medicine, Inc. as intermediary for the Research Institute of Tropical Medicine (RITM)
Muntinlupa City, Philippines
$20,000*

Adeeba Kamarulzaman, M.B.B.S., F.R.A.C.P.
University of Malaya
Kuala Lumpur, Malaysia
$20,000*

Pacharee Kantipong, M.D.
Chiangrai Prachanukroh Hospital
Chiang Rai, Thailand
$15,500

Sasisopin Kiertiburanakul, M.D., M.H.S.
Ramathibodi Hospital, Mahidol University
Bangkok, Thailand
$20,000*

Nguyen Van Kinh, M.D., Ph.D.
National Hospital of Tropical Diseases
Hanoi, Vietnam
$20,000*

Nagalingeswaran Kumarasamy, M.D., M.B.B.S., Ph.D.
YRG Centre for AIDS Research and Education, VHS
Chennai, India
$20,000*

Christopher Lee, M.B.B.S., M.R.C.P.
Sungai Buloh Hospital
Sungai Buloh, Malaysia
$15,000*

Patrick Li, M.B.B.S.
Queen Elizabeth Hospital
Hong Kong, China
$20,000*

Tuti Parwati Merati, M.D., Ph.D.
Udayana University School of Medicine
Denpasar, Indonesia
$20,000*

*Supported with funds from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number U01AI069907.

TREAT ASIA HIV OBSERVATIONAL DATABASE TAHOD

Oon Tek Ng, M.B.B.S., M.R.C.P.
Tan Tock Seng Hospital
Singapore, Singapore
$16,000*

Shinichi Oka, M.D., Ph.D.
National Center for Global Health and Medicine
Shinjuku, Japan
$16,000*

Praphan Phanuphak, M.D., Ph.D.
HIV-NAT / Thai Red Cross AIDS Research Center
Bangkok, Thailand
$20,000*

Sanjay Pujari, M.D.
Institute of Infectious Diseases
Pune, India
$20,000*

Winai Ratanasuwan, M.D.
Siriraj Hospital, Mahidol University
Bangkok, Thailand
$7,850

Pham Thi Thanh Thuy, M.D.
Bach Mai Hospital
Hanoi, Vietnam
$20,000*

Saphonn Vonthanak, M.D., Ph.D.
National Center for HIV/AIDS, Dermatology & STDs / Cambodia National Institute of Public Health
Phnom Penh, Cambodia
$20,000*

Evy Yunihastuti, M.D., Ph.D.
Cipto Mangunkusumo General Hospital
Jakarta, Indonesia
$20,000*

Fuje Zhang, M.D.
Beijing Ditan Hospital, Capital Medical University
Beijing, China
$16,000*

TAHOD STUDY ON THE SOCIO-ECONOMIC DETERMINANTS OF TUBERCULOSIS IN ASIA

Rossana Ditangco, M.D.
Asian Foundation for Tropical Medicine, Inc. as intermediary for the Research Institute of Tropical Medicine (RITM)
Muntinlupa City, Philippines
$15,114*

Adeeba Kamarulzaman, M.B.B.S., F.R.A.C.P.
University of Malaya
Kuala Lumpur, Malaysia
$10,164*

Sasisopin Kiertiburanakul, M.D., M.H.S.
Ramathibodi Hospital, Mahidol University
Bangkok, Thailand
$8,702*

Patrick Li, M.B.B.S.
Queen Elizabeth Hospital
Hong Kong, China
$3,000*

Tuti Parwati Merati, M.D., Ph.D.
Udayana University
Denpasar, Indonesia
$24,274*

Oon Tek Ng, M.B.B.S., M.R.C.P.
Tan Tock Seng Hospital
Singapore, Singapore
$8,250*
Praphan Phanuphak, M.D., Ph.D.
HIV-NAT / Thai Red Cross AIDS Research Center
Bangkok, Thailand
$8,244*

Pham Thi Thanh Thuy, M.D.
Bach Mai Hospital
Hanoi, Vietnam
$13,740*

Nguyen Van Kinh, M.D., Ph.D.
National Hospital of Tropical Diseases
Hanoi, Vietnam
$18,320*

Fujie Zhang, M.D.
Beijing Ditan Hospital, Capital Medical University
Beijing, China
$8,244*

Matthew G. Law, Ph.D.
University of New South Wales
Sydney, Australia
$18,575

Debbie Allen, M.B.Ch.B., Dip.
Central Coast Local Health District
Gosford, Australia
$1,800

Andrew Carr, M.D.
St. Vincent’s Hospital
Darlinghurst, Australia
$7,350*

Katherine Brown, M.D.
Illawarra Shoalhaven Local Health District
Wollongong, Australia
$1,800

William Donohue, M.B.B.S.
O’Brien Street Practice
Adelaide, Australia
$2,025

Jennifer Hoy, M.B.B.S.
Victorian HIV Service, Infectious Diseases Department, The Alfred Hospital
Melbourne, Australia
$6,300*

Eva Jackson, M.B.B.S.
Blue Mountains Sexual Health and HIV Clinic
Katoomba, Australia
$1,350

Mark Kelly, M.B.B.S.
Prince Charles Hospital, Brisbane Sexual Health and HIV Service
Brisbane, Australia
$7,125*

David Nolan
Royal Perth Hospital
Perth, Australia
$5,550*

Tim Read
Melbourne Sexual Health Centre
Carlton, Australia
$6,525*

Norman Roth, M.B.B.S., FA.Ch.S.H.M.
Prahran Market Clinic Pty Ltd.
South Yarra, Australia
$6,450*

Darren Russell, M.D.
Ca irns Sexual Health Service
Cairns, Australia
$6,225*

Nathan Ryder, M.D.
Northern Territory Dept of Health & Community Services, Sexual Health & Blood Borne Virus Program
Darwin, Australia
$1,350

David Smith
Sexual Health and AIDS Services (SHAIDS)
Lismore, Australia
$6,900*

David Sowden, M.B.B.S
Nambour General Hospital
Nambour, Australia
$7,500*

Sharon Taylor, C.N.C.
Hunter New England Health, Clinic 468, Tamworth Sexual Health Service
Tamworth, Australia
$975

David Templeton, Ph.D.
RPA Sexual Health Clinic
Camperdown, Australia
$600

Rick Varma, MRCP
Nepean Sexual Health Clinic
Kingswood, Australia
$900

Ian Woolley, M.B.B.S., F.R.A.C.P.
Southern Health
Monash Medical Centre - Clayton
Melbourne, Australia
$4,725

Lynne Wray, M.B.B.S.
Sydney Sexual Health Centre, Sydney Hospital
Sydney, Australia
$5,175*

A Cambodian clinical research network for HIV and TB
Sok Thim, M.D. and Anne Goldfeld, M.D.
Global Health Committee, Inc.
Boston, MA
$297,750*

A randomized open-label study of second-line ART
David Cooper, M.D.
University of New South Wales
Sydney, Australia
$100,000

Teman-Teman, Indonesia
Jintanat Ananworanich, M.D., Ph.D.
Thai Red Cross AIDS Research Center, SEARCH
Bangkok, Thailand
$2,991

PEDIATRIC RESEARCH
TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TAPhOD)
Jintanat Ananworanich, M.D.
HIV-NAT / Thai Red Cross AIDS Research Center
Bangkok, Thailand
$18,680

Kulkanya Chokephaibulkit, M.D.
Siriraj Hospital, Mahidol University
Bangkok, Thailand
$23,435

Rawiwan Hansudewechakul, M.D.
Chiangrai Prachanukroh Hospital
Chiangrai, Thailand
$25,780

Trương Hữu Khanh, M.D.
Children’s Hospital 1
Ho Chi Minh City, Vietnam
$29,280

Nagalingeswaran Kumarasamy, M.D., M.B.B.S.
YRG Centre for AIDS Research and Education, VHS
Chennai, India
$18,575

Incorporating high resolution anoscopy in AIN screening and treatment programs for MSM in Indonesia, Malaysia, and Thailand
Nittaya Phanuphak, M.D.
HIV-NAT / Thai Red Cross AIDS Research Center
Bangkok, Thailand
$175,000

Study on anal human papillomavirus infection and anal intraepithelial neoplasia among MSM in Indonesia, Malaysia, and Thailand
Nittaya Phanuphak, M.D., Ph.D.
HIV-NAT / Thai Red Cross AIDS Research Center
Bangkok, Thailand
$200,000

Asia Pacific HIV Research Collaboration: Cancer Studies
Matthew G. Law, Ph.D.
University of New South Wales
Sydney, Australia
$38,202*

Asia Pacific HIV Research Collaboration: Data Harmonization
Matthew G. Law, Ph.D.
University of New South Wales
Sydney, Australia
$36,719*

Individual projects
Asia Pacific HIV Research Collaboration: AHOD, Suicide Study
Matthew G. Law, Ph.D.
University of New South Wales
Sydney, Australia
$212,770*

Identifying Biomarkers of Anal Intraepithelial Neoplasia in Thai MSM
Nittaya Phanuphak, M.D.
HIV-NAT / Thai Red Cross AIDS Research Center
Bangkok, Thailand
$100,000*

Incorporating high resolution anoscopy in AIN screening and treatment programs for MSM in Indonesia, Malaysia, and Thailand
Nittaya Phanuphak, M.D.
HIV-NAT / Thai Red Cross AIDS Research Center
Bangkok, Thailand
$175,000

Study on anal human papillomavirus infection and anal intraepithelial neoplasia among MSM in Indonesia, Malaysia, and Thailand
Nittaya Phanuphak, M.D., Ph.D.
HIV-NAT / Thai Red Cross AIDS Research Center
Bangkok, Thailand
$200,000

Asia Pacific HIV Research Collaboration: Cancer Studies
Matthew G. Law, Ph.D.
University of New South Wales
Sydney, Australia
$38,202*

Asia Pacific HIV Research Collaboration: Data Harmonization
Matthew G. Law, Ph.D.
University of New South Wales
Sydney, Australia
$36,719*

A Cambodian clinical research network for HIV and TB
Sok Thim, M.D. and Anne Goldfeld, M.D.
Global Health Committee, Inc.
Boston, MA
$297,750*
Nguyen Van Lam, M.D., MSC
Cipto Mangunkusumo General Hospital
Jakarta, Indonesia
$18,500

Kamarul Razali, M.D.
National Hospital of Pediatrics
Jakarta, Indonesia
$18,500

Nia Kurniati, M.D.
Cipto Mangunkusumo General Hospital
Jakarta, Indonesia
$21,570

Do Chau Viet, M.D.
Children’s Hospital 2
Ho Chi Minh City, Vietnam
$19,280

Virat Sirisanthana, M.D.
Chiang Mai University-Research Institute for Health Sciences
Chiang Mai, Thailand
$16,500

Do Chau Viet, M.D.
Children’s Hospital 2
Ho Chi Minh City, Vietnam
$23,500

(Individual projects)

Optimizing HIV Treatment for Children In Asia: Developing Strategies for Lifelong Care
Prapphan Phanuphak, M.D., Ph.D.
HIV-NAT / Thai Red Cross AIDS Research Center
Bangkok, Thailand
$4,000 (supplement to funding for previous year) $147,273

Effect of socioeconomic factors on cognition, adaptive function and school status
Jintanat Ananworanich, M.D., Ph.D.
HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)
Bangkok, Thailand
$50,000

Study of atazanavir/ritonavir-based HAART in Thai HIV-infected children
Torsak Bunupuradah, M.D.
HIV-NAT / Thai Red Cross AIDS Research Center
Bangkok, Thailand
$42,342

Understanding adherence, stigma, and behavioral risk factors of adolescents in TAPHOD using audio computer assisted self-interview (ACASI)
Wasana Prasitsuebsai, M.D., M.PH.
HIV-NAT / Thai Red Cross AIDS Research Center
Bangkok, Thailand
$12,000*

Bone Mineral Density Among HIV-infected Adolescents
Kulkanya Chokephaibulkit, M.D.
Siriraj Hospital, Mahidol University
Bangkok, Thailand
$10,000*

Cardiovascular abnormalities and carotid intima-media thickness among HIV-infected adolescents in Thailand
Kulkanya Chokephaibulkit, M.D.
Siriraj Hospital, Mahidol University
Bangkok, Thailand
$42,726

Treatment response of chronic viral hepatitis B to tenofovir and lamivudine-containing antiretroviral regimens in HIV-infected adolescents
Linda Auripibul, M.D.
Chiang Mai University
Chiang Mai, Thailand
$9,433* / $8,603

Social Support for Children and Adolescents with HIV
Fong Siew Moy, M.D.
Hospital Likas
Kota Kinabalu, Malaysia
$10,000

Interventions to Promote Retention in Formal School System
Jintanat Ananworanich, M.D.,
HIV-NAT / Thai Red Cross AIDS Research Center
Bangkok, Thailand
$10,922

Providing knowledge about HIV and sex education for HIV positive and disclosed adolescents and their caregivers in Ho Chi Minh City
Le Ngoc Oanh, M.D.
Worldwide Orphans Foundation
Kuala Lumpur, Malaysia
$2,000

Plan for supportive discussion groups for adolescents from below 10 to 15 years of age
Do Chau Viet, M.D.
Children’s Hospital 2
Ho Chi Minh City, Vietnam
$2,000

Monkey Meeting
John Tucker
New Hope for Cambodian Children
Killeen, TX
$2,000

Reinforcing on HIV disclosure and follow-up of HIV infected children and adolescents in National Pediatric Hospital
Ung Vibol, M.D.
National Pediatric Hospital
Phnom Penh, Cambodia
$2,000

Psychosocial support for children and adolescents living with HIV/AIDS
Nia Kurniati, M.D.,
Cipto Mangunkusumo General Hospital
Jakarta, Indonesia
$2,000

Our Village
John Tucker
New Hope for Cambodian Children
Killeen, TX
$175,004
### 2012 GMT INITIATIVE AWARDS

#### GMT INITIATIVE COMMUNITY AWARDS

**Africa**

- **MSM Participation in the response against AIDS in Burundi**
  - Reseau National Des Jeunes Engages Dans La Lutte Contre Le VIH/SIDA
  - Bujumbura, Burundi
  - $12,080

- **Awareness, Capacity Building and Treatment/Care Health Options For Young Men on HIV, AIDS and STIs**
  - Nairobi, Kenya
  - $20,100

- **Evidence Based Target HIV Prevention Project**
  - Centre for the Development of People
  - Lilongwe, Malawi
  - $12,080

- **Breaking Down the Taboos and Raising Awareness amongst MSM on HIV and AIDS**
  - WhyCantWeGetMarried.Com West Africa Chapter
  - Awareness, Capacity Building and Treatment/Care
  - $20,000

- **Icebreakers Uganda MSM Initiative**
  - Spectrum Uganda Initiatives
  - Kampala, Uganda
  - $12,500

**Asia-Pacific**

- **PCA , Empowerment, Advocacy: Improve the Living Status of TG in Chengdu, China**
  - Chengdu Tongle Counseling and Service Center
  - Chengdu, China
  - $19,970

- **Internet-based Advocacy and Empowerment of Sexual Health Rights for MSM Youth**
  - GZTZ.ORG
  - Guangzhou, China
  - $12,000

- **HIV Intervention in Male Massage Centers**
  - Name withheld by request
  - Sri Lanka
  - $15,567

- **Supporting Burmese MSM Migrant Workers in Southern Thailand Year 2**
  - The Human Rights Education Institute of Burma (HREIB)
  - Chiang Mai, Thailand
  - $19,958

- **Caribbean**
  - **Working Together to Enhance the MSM Community in Antigua and Barbuda**
    - Antigua Resilience Collective Inc. (ARC)
    - St. John’s, Antigua and Barbuda
    - $10,000

  - **Scaling Up the Quality and Quantity of Life of MSM Living with HIV in Belize**
    - Collaborative Network of Persons Living with HIV (C-NET+)
    - Belize City, Belize
    - $19,987

  - **Empowering Male Sex Workers and Transgender Populations in San Pedro de Macoris**
    - Grupo Este Amor
    - La Romana, Dominican Republic
    - $19,908

  - **Deepening Outreach to Hearing Impaired MSM in Jamaica**
    - Jamaica AIDS Support for Life (JASL)
    - Kingston, Jamaica
    - $20,000

  - **Fight the Hate: Mitigating Risks and Enabling Safe Spaces for LGBT Jamaicans**
    - Jamaica Forum for Lesbians, All-Sexuals & Gays (J-FLAG)
    - Kingston, Jamaica
    - $20,000

  - **Leadership Development and Social Support for Tertiary LGBT in Jamaica**
    - PRIDE In Action
    - Kingston, Jamaica
    - $12,495

  - **Challenging Self Stigma and Discrimination While Raising Awareness**
    - United and Strong Inc.
    - Gros Islet, Saint Lucia
    - $10,000

  - **Homophobia Causes AIDS, Organizing Can End It**
    - Coalition Advocating for Inclusion of Sexual Orientation (CAISO)
    - Port of Spain, Trinidad and Tobago
    - $10,000

  - **Improving the Service Delivery Model for GLBT, MSM/TG & Male Sex Workers in Trinidad & Tobago**
    - Friends For Life
    - Port-of-Spain, Trinidad and Tobago
    - $15,000

- **Eastern Europe and Central Asia**

  - **Access to HIV-Related Services for Transgender Individuals in the South Caucasus**
    - Center for Information and Counseling on Reproductive Health–Tanadgoma
    - Tbilisi, Georgia
    - $19,970

  - **Bringing Safety and Security for the Local GBT Community**
    - Public Association Kyrrgyz Indigo
    - Bishkek, Kyrgyzstan
    - $19,663

  - **Organizational and Educational Work with Third Age MSM: Our Response to HIV/AIDS**
    - GENDERDOC-M Information Centre
    - Chisinau, Republic of Moldova
    - $19,975

- **Community Based VCT on HIV among MSM**

  - **Population in Belgrade as an Additional Measurement for HIV Prevention**
    - Safe Pulse of Youth (SPY)
    - Belgrade, Serbia
    - $8,000

  - **Accessible, Quality and Reliability, on Equal Terms NGO Equall Opportunities**
    - Dushanbe, Tajikistan
    - $20,000

  - **Increasing Access to HIV Prevention, Care and Support for MSM in Prisons**
    - Nikolaev Regional Public Youth Movement
    - Penitentiary Initiative
    - Nikolaev, Ukraine
    - $15,000

  - **Medical and Social Support, HIV Prevention among Gay Men and MSM**
    - Public Youth Organization Self Help Club Life + Odessa, Ukraine
    - $20,000

- **Latin America**

  - **Acceso Universal para población Trans que se dedica al trabajo Sexual**
    - Mesa De Trabajo Nacional Cochabamba, Bolivia
    - $20,000

  - **Incidencia en los tomarones de decisiones para la mejora de los presupuestos y políticas públicas de prevención en VIH/SIDA en gays, trans y otros HSH en Chile**
    - CES / MUMS Movimiento Por La Diversidad Sexual Santiago, Chile
    - $20,000

  - **Análisis de las Trans y los factores en aumento del VIH y Discriminación**
    - Asociación Silueta X
    - Guayaquil, Ecuador
    - $19,920

  - **Atención Médica, Psicológica y Prevención del VIH-Sida para HSH**
    - Asociación ALFIL
    - Quito, Ecuador
    - $19,530

  - **Proyecto Abriendo Caminos**
    - Asociación Solidaria Para Impulsar El Desarrollo Humano (ASPI-DH ARCO IRIS)
    - San Salvador, El Salvador
    - $20,000

  - **Increased participation of trans people in public policies on HIV and AIDS**
    - Fundacion Llantto, Valor y Esfuerzo (LLAVES)
    - San Pedro Sula, Honduras
    - $19,450

  - **Sensibilizando a hombres jóvenes indígenas mayas que tienen sexo con otros hombres**
    - Centro de Desarrollo e Investigación sobre Juventud, A.C.
    - Campeche, Mexico
    - $15,615

  - **Atención Integral para Gays y HSH en la Región Metropolitana de Panamá**
    - Grupo Génesis Panamá Positivo (GGP+)
    - Panama, Panama
    - $20,000
Centro Fijo y Movil de Consejeria y Testeo Voluntario en Asuncion
Asociación Civil SOMOSGAY
Asuncion, Paraguay
$20,000

Alma Chalaca: Innovative Workshops by and for MSM/Transgender PEPs in Lima/Callao, Peru
Asociacion Civil Impacta Salud y Educacion Lima, Peru
$10,985

Concertando Diversidades Para la Prevencion del VIH y Derechos Humanos Para HSH en la Region San Martin-Peru 2011-2012
Asociación Diversidad San Martinense Tarapoto, Peru
$20,000

HSH, poblacion transgenero, VIH y los servicios de salud en Uruguay
Collectivo Ovejas Negras Montevideo, Uruguay
$14,500

ADVOCACY IN ACTION AWARDS

Advocacy in Action Program – China 2012
Beijing Ark of Love PLWHA Supporting Group as sponsor for Nanjing Joyful Life Group
Beijing, China
$17,000

Advocacy in Action – Lao PDR
Lao Positive Health Association (LaoPHA) Vientiane, Lao PDR
$6,000

Advocacy in Action – Nepal
Blue Diamond Society Kathmandu, Nepal
$14,250

Advocacy in Action Program – Thailand 2012
Health and Opportunity Network (HON) T-Nongpue-Banglamoong, Thailand
$6,000

Advocacy In Action – Vietnam: Supplement for Project Completion
Institute for Studies of Society, Economy and Environment (ISEE) Hanoi, Vietnam
$1,481

EVIDENCE IN ACTION AWARDS

Access to HIV Services
Bandhu Social Welfare Society (BSWS) Dhaka, Bangladesh
$23,919

Screening Project
Alternatives-Cameroun Douala, Cameroon
$24,000

Promoting Universal Access, behavioural change and community building for MSM in Grenada GrenCHAP Inc. St. George, Grenada
$24,000

Contributing to the increment of men who have sex with men (MSM) who attend voluntarily to take HIV testing with pre and post counseling
Asociacion De Hombres Y Mujeres Nuevos De Panama Panama, Panama
$24,000

Iguales/Equals/Nande Joja
SOMOSGAY Asunción, Paraguay
$24,000

PULSAR, Power of Evidence
The Center for Health and Social Support (SIBALT) Omsk, Russia
$24,000

GMT INITIATIVE AWARDS

Increasing Access to high-quality, integrated STI/HIV services for men who have sex with men in Bali, Indonesia
Yayasan Kasih Suwitno (YKS) Jakarta, Indonesia
$25,000

A health sector intervention to increase the competence and sensitivity of health care services for gay men and other MSM in Malawi
Fenway Community Health Center, Inc. Boston, MA
$25,000

Pre-conference programs: AIDS 2012
Phill Wilson Black AIDS Institute
Los Angeles, CA
$75,000

We Can! We Will! End AIDS!
Paul Zeitz, D.O., M.P.H. The End of AIDS, Inc. Wilmington, DE
$125,000

GLOBAL ADVOCACY CORPS AWARDS

Strengthening the capacity of CSOs to monitor and influence health, HIV and TB budgets and expenditures in Zimbabwe
Nhlanhla Ndlovu Centre for Economic Governance and AIDS in Africa Cape Town, South Africa
$60,555

Beginning to end AIDS: civil society advocacy to scale up high impact prevention and treatment interventions in Malawi
Rodney Chalera Centre for the Development of People (CEDEP) Lilongwe, Malawi
$16,200

2012 PUBLIC POLICY GRANTS AND AWARDS

Northeast Florida AIDS Network
Donna M. Fuchs Northeast Florida AIDS Network
Jacksonville, FL
$2,000

Don C. Des Jarlais, Ph.D. Beth Israel Medical Center - Edmond de Rothschild Chemical Dependency Institute
New York, NY
$90,000

Barriers to Reason: Laws Impacting HIV Prevention Efforts among IDUs in the United States
Don C. Des Jarlais, Ph.D. Beth Israel Medical Center
New York, NY
$90,000

National Minority AIDS Council – 25th Anniversary
Paul Kawata National Minority AIDS Council
Washington, DC
$25,000

A training program for HIV research among MSM in developing world settings
Ronald D. Stall, Ph.D., M.P.H. University of Pittsburgh
Pittsburgh, PA
$125,000
We are pleased to present the audited financial statements of amfAR, The Foundation for AIDS Research, for the fiscal year ending September 30, 2012.

Public support and revenue increased by 4.1 percent over the previous year, to $28.3 million. Due mainly to an increase of $1.2 million in research spending, however, amfAR ended the year with a modest operating deficit of $687,981.

amfAR’s operational efficiency during 2012 is illustrated by a low supporting services ratio—the ratio of fundraising and management expenses to total support and revenue—of 24.7 percent. And of every dollar spent, 75.9 percent was invested directly in critical program activities, demonstrating effective use of donor contributions.

The Foundation’s steady growth in 2012 was accompanied by important programmatic advances. For example, new grants were awarded to collaborative teams of senior scientists pursuing a cure for AIDS through the amfAR Research Consortium on HIV Eradication (ARCHE). In year three of ARCHE, grantees made impressive progress.

In 2012, amfAR again met the stringent requirements of governance and financial accountability demanded by the Better Business Bureau’s Wise Giving Alliance and was designated a four-star charity—the highest possible rating—by Charity Navigator. The Foundation also met the strict requirements of the federal government’s workplace fundraising program, the Combined Federal Campaign, as well as many state employee workplace giving campaigns.

A copy of the complete audited financial statements, prepared in accordance with generally accepted accounting principles for not-for-profit organizations as established by the American Institute of Certified Public Accountants, is available upon request from amfAR at 120 Wall Street, 13th Floor, New York, NY 10005, and can be accessed by visiting www.amfar.org.

Wallace Sheft, C.P.A.
Treasurer

Michael J. Klingensmith
Chair, Finance and Budget Committee
Financial Highlights
For the year ended September 30, 2012

Public Support and Revenue

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public support</td>
<td>$6,780,112</td>
</tr>
<tr>
<td>Special events</td>
<td>11,606,820</td>
</tr>
<tr>
<td>Planned giving</td>
<td>2,862,378</td>
</tr>
<tr>
<td>Government funding</td>
<td>5,008,478</td>
</tr>
<tr>
<td>Investment income and other revenue</td>
<td>2,021,109</td>
</tr>
<tr>
<td><strong>Total public support and revenue</strong></td>
<td><strong>$28,278,897</strong></td>
</tr>
</tbody>
</table>

Expenses

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$8,725,334</td>
</tr>
<tr>
<td>TREAT Asia</td>
<td>5,740,985</td>
</tr>
<tr>
<td>GMT Initiative</td>
<td>2,046,655</td>
</tr>
<tr>
<td>Public Policy</td>
<td>2,317,793</td>
</tr>
<tr>
<td>Public Information</td>
<td>3,159,567</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td><strong>$21,990,334</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundraising</td>
<td>4,754,301</td>
</tr>
<tr>
<td>Management and general</td>
<td>2,222,243</td>
</tr>
<tr>
<td><strong>Total supporting services</strong></td>
<td><strong>$6,976,544</strong></td>
</tr>
</tbody>
</table>

| Total expenses                        | **$28,966,878** |

Change in net assets

| Change in net assets                  | ($687,981) |
| Net assets, beginning of year         | 31,440,085  |

| Net assets, end of year               | $30,752,104 |

Statement of Financial Position

Assets

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and investments</td>
<td>$29,362,802</td>
</tr>
<tr>
<td>Pledges and receivables</td>
<td>8,162,387</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>974,399</td>
</tr>
<tr>
<td>Furniture, equipment, and leasehold improvements</td>
<td>1,888,607</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$40,388,195</strong></td>
</tr>
</tbody>
</table>

Liabilities

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$1,732,740</td>
</tr>
<tr>
<td>Grants and fellowships payable, net</td>
<td>1,713,122</td>
</tr>
<tr>
<td>Deferred support and refundable advances</td>
<td>5,428,345</td>
</tr>
<tr>
<td>Other long-term liabilities</td>
<td>761,884</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>$9,636,091</strong></td>
</tr>
</tbody>
</table>

| Total net assets                                      | 30,752,104 |

| Total liabilities and net assets                      | **$40,388,195** |
**Expenses**

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundraising</td>
<td>$4,754,301</td>
</tr>
<tr>
<td>Management and general</td>
<td>$2,222,243</td>
</tr>
<tr>
<td>Program</td>
<td>$21,990,334</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$28,966,878</strong></td>
</tr>
</tbody>
</table>

**Program Expenses**

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$8,725,334</td>
</tr>
<tr>
<td>TREAT Asia</td>
<td>$5,740,985</td>
</tr>
<tr>
<td>GMT Initiative</td>
<td>$2,046,655</td>
</tr>
<tr>
<td>Public Policy</td>
<td>$2,317,793</td>
</tr>
<tr>
<td>Public Information</td>
<td>$3,159,567</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$21,990,334</strong></td>
</tr>
</tbody>
</table>
BOARD OF TRUSTEES
Fiscal Year 2012

Chairman of the Board
Kenneth Cole
Chairman
Kenneth Cole Productions
New York, NY

Founding Chairman
Mathilde Krim, Ph.D.
Adjunct Professor
Mailman School of Public Health
Columbia University
New York, NY

Vice Chairman
Patricia J. Matson
Senior Vice President, Communications (ret.)
ABC, Inc.
New York, NY

Vice Chairman
John C. Simons
Managing Partner
Corporate Fuel Partners, LLC
New York, NY

Treasurer
Wallace Sheft, C.P.A.
Partner (ret.)
Wurmband, Lerner & Sheft
Westbury, NY

Secretary
Mervyn F. Silverman, M.D., M.P.H.
Crockett, CA

TRUSTEES

Arlen H. Andelson
Andelson Properties
Los Angeles, CA

Harry Belafonte
President
Belafonte Enterprises, Inc.
New York, NY

David Bohnett
Chairman
David Bohnett Foundation
Beverly Hills, CA

Zev Braun
President and CEO
Braun Entertainment Group, Inc.
Beverly Hills, CA

Jonathan S. Canno
New York, NY

Donald A. Capoccia
Managing Principal
BFC Partners
Brooklyn, NY

R. Martin Chavez, Ph.D.
Managing Director
Goldman, Sachs & Co.
New York, NY

Jane B. Eisner
Bel Air, CA

T. Ryan Greenawalt
President/Founder
Harrison Street Productions
New York, NY

Regan Hofmann
Global Health Consultant
Ringoes, NJ

Michael J. Klingensmith
CEO and Publisher
Minneapolis Star Tribune
Minneapolis, MN

Michele V. McNeil, Pharm.D.
Long Boat Key, FL

Edward L. Milstein
Co-Chairman
Milstein Brothers Capital Partners
New York, NY

Cindy D. Rachofsky
Philanthropist
Dallas, TX

Vincent A. Roberti
Chairman, Roberti+White
Washington, D.C.
CEO
Palisades Media Corp.
New York, NY

Bill Roedy
London, UK

Raymond F. Schinazi, Ph.D., D.Sc.
Frances Winship Walters Professor
Director, Laboratory of Biochemical Pharmacology
Emory University
Decatur, GA

Alan D. Schwartz
Executive Chairman
Guggenheim Partners LLC
New York, NY

Diana L. Taylor
Managing Director
Wolfensohn & Co. LLC
New York, NY

Kevin Wendle
Entrepreneur
Paris, France

TRUSTEES EMERITI

Arthur J. Ammann, M.D.
President, Global Strategies for HIV Prevention
Clinical Professor of Pediatrics
University of California, San Francisco
Medical Center
San Rafael, CA

Arnold W. Klein, M.D.
Professor of Medicine/Dermatology
University of California, Los Angeles
Beverly Hills, CA

HONORARY TRUSTEES

Mouna E. Ayoub
Paris, France

John F. Breglio, Esq.
Paul, Weiss, Rifkind, Wharton & Garrison
New York, NY

Robert L. Burkett
The Carmen Group
Washington, D.C.

Michael Fuchs
New York, NY

Sandra Hernández, M.D.
Chief Executive Officer
The San Francisco Foundation
San Francisco, CA

Sherry Lansing
Chief Executive Officer/Founder
The Sherry Lansing Foundation
Los Angeles, CA

Jane F. Nathanson
Psychologist
Chair, Jane & Marc Nathanson
Community Foundation
Los Angeles, CA

The Rev. Dr. Randolph Nugent
General Secretary (ret.)
General Board of Global Ministries
United Methodist Church
New York, NY

Leonard Rabinowitz
President
Studio CL
Los Angeles, CA

Michael D. Shriver
Co-Director, AIDS Policy Research Center
AIDS Research Institute
University of California, San Francisco
San Francisco, CA

IN MEMORIAM

Sheldon W. Andelson, Esq.
MRS. ALBERT D. LASKER
Jonathan M. Mann, M.D., M.P.H.
Maxine Mesinger
Pauline Phillips
Natasha Richardson
Allan Rosenfield, M.D.
Peter Scott, Esq.
Tom Stoddard
Joel D. Weisman, D.O.
### Scientific Advisory Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Designation</th>
<th>Institution/Program</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mario Stevenson, Ph.D. (Chair)</td>
<td>Professor</td>
<td>University of Miami</td>
</tr>
<tr>
<td>Jintanat Ananworanich, M.D.</td>
<td>Professor</td>
<td>Boston University School of Medicine</td>
</tr>
<tr>
<td>Deborah Anderson, Ph.D.</td>
<td>Professor and Director</td>
<td>Department of Reproductive Biology</td>
</tr>
<tr>
<td>Warren A. Andiman, M.D.</td>
<td>Professor of Pediatrics, Epidemiology and Public Health</td>
<td>Yale University School of Medicine</td>
</tr>
<tr>
<td>Michael Betts, Ph.D.</td>
<td>Assistant Professor</td>
<td>University of Pennsylvania School of Medicine</td>
</tr>
<tr>
<td>Jason Brenchley, Ph.D.</td>
<td>Investigator</td>
<td>Vaccine Research Center National Institute of Allergy and Infectious Diseases National Institutes of Health</td>
</tr>
<tr>
<td>Dennis R. Burton, Ph.D.</td>
<td>Professor</td>
<td>The Scripps Research Institute</td>
</tr>
<tr>
<td>Salvatore T. Butera, D.V.M., Ph.D.</td>
<td>Chief Science Officer</td>
<td>Sciips CHAVI-ID</td>
</tr>
<tr>
<td>Edward Campbell, Ph.D.</td>
<td>Assistant Professor</td>
<td>Loyola University at Chicago</td>
</tr>
<tr>
<td>Alex Carballo-Diequez, Ph.D.</td>
<td>Research Scientist and Associate Professor of Clinical Psychology HIV Center, NYS Psychiatric Institute Columbia University</td>
<td></td>
</tr>
<tr>
<td>Jae-Wook Chun, Ph.D.</td>
<td>Staff Scientist</td>
<td>National Institute of Allergy and Infectious Diseases National Institutes of Health</td>
</tr>
<tr>
<td>David B. Clifford, M.D.</td>
<td>Professor</td>
<td>Washington University School of Medicine</td>
</tr>
<tr>
<td>C. Budd Colby, Ph.D.</td>
<td>Principal</td>
<td>Colby Biomedical Consultants</td>
</tr>
<tr>
<td>Grant Colfax, M.D.</td>
<td>Director of HIV Prevention and Research</td>
<td>San Francisco Department of Public Health</td>
</tr>
<tr>
<td>Deborah Jean Cotton, M.D., M.P.H.</td>
<td>Professor of Medicine</td>
<td>Boston University School of Medicine</td>
</tr>
</tbody>
</table>

### Board Committees

#### Executive Committee
- Kenneth Cole, Chair
- Michael J. Klingensmith
- Mathilde Krim, Ph.D.
- Patricia J. Matson
- Vincent A. Roberti
- Wallace Sheft, C.P.A.
- Mervyn F. Silverman, M.D., M.P.H.
- John C. Simons

#### Audit Committee
- Wallace Sheft, C.P.A., Chair
- R. Martin Chavez, Ph.D.
- John C. Simons

#### Board Development Committee
- John C. Simons, Chair
- David Bohnett
- Mathilde Krim, Ph.D.
- Patricia J. Matson
- Mervyn F. Silverman, M.D., M.P.H.
- John C. Simons

#### Finance & Budget Committee
- Michael J. Klingensmith, Chair
- Vincent A. Roberti
- John C. Simons

#### Fund Development Committee
- Vincent A. Roberti, Chair
- Jonathan S. Canno
- Edward L. Milstein

#### Investment Committee
- Michael J. Klingensmith, Chair
- R. Martin Chavez, Ph.D.
- Edward L. Milstein
- Vincent A. Roberti
- Wallace Sheft, C.P.A.
- John C. Simons
PROGRAM ADVISORY COUNCIL

Mervyn F. Silverman, M.D., M.P.H. (Chairman)
President
Mervyn F. Silverman Associates, Inc.

David E. Bloom, Ph.D. (Co-Chairman)
Department of Global Health and Population
Harvard School of Public Health

Mario Stevenson, Ph.D. (Co-Chairman)
Professor of Medicine
Chief, Division of Infectious Diseases
Leonard M. Miller School of Medicine
University of Miami

Tim Brown, Ph.D.
Senior Fellow
The East-West Center

Daria J. Hazuda, Ph.D.
Vice President of Scientific Affairs for Infectious Disease
Merck & Company, Inc.

Kenneth H. Mayer, M.D.
Infectious Disease Attending & Director of HIV Prevention Research
Beth Israel Deaconess Medical Center
Visiting Professor of Medicine
The Fenway Institute/Fenway Health

Jeffrey L. Sturchio, Ph.D.
Senior Partner
Rabin Martin
The Institute for Applied Economics, Global Health and the Study of Business Enterprise, Johns Hopkins University
Member of The Council on Foreign Relations

Phill Wilson
Chief Executive Officer and President
The Black AIDS Institute

MANAGEMENT GROUP

Kevin Robert Frost
Chief Executive Officer

Anthony Ancona
Vice President and Director, Human Resources

Susan J. Blumenthal, M.D., M.P.A.
Senior Policy and Medical Advisor

Gregory Boroff, C.A.E., C.F.R.E.
Vice President and Director, Development

Chris Collins, M.P.P.
Vice President and Director, Public Policy

Bradley Jensen
Chief Financial Officer

Rowena Johnston, Ph.D.
Vice President and Director, Research

Jeffrey Laurence, M.D.
Senior Scientific Consultant for Programs

John F. Logan, Ph.D., J.D.
Vice President and General Counsel

AnnMari Shannahan
Vice President, Public Information

Annette Sohn, M.D.
Vice President and Director, TREAT Asia